L-DOPA DOES NOT AFFECT ELECTRON-TRANSFER CHAIN ENZYMES AND RESPIRATION OF RAT MUSCLE MITOCHONDRIA

被引：19

作者：

DAGANI, F

FERRARI, R

ANDERSON, JJ

CHASE, TN

机构：

[1] Istituto di Farmacologia, Facoltà di Scienze Mm.Ff.Nn, University of Pavia

[2] Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland

[3] Istituto di Farmacologia, Facoltà di Scienze Mm.Ff.Nn, Università di Pavia, Pavia, 27100

来源：

MOVEMENT DISORDERS | 1991年 / 6卷 / 04期

关键词：

L-DOPA; SKELETAL MUSCLE MITOCHONDRIA; RESPIRATION; ENZYME ACTIVITIES;

D O I：

10.1002/mds.870060408

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Alterations in mitochondrial respiratory chain enzymes have been found in skeletal muscle of parkinsonian patients. Most of these patients had received treatment with L-dopa in combination with an inhibitor of peripheral decarboxylase for several years. In order to determine whether these effects are only dependent on the disease or are partially due to its therapy, the effects of L-dopa methyl ester and benserazide, a peripheral dopa decarboxylase inhibitor, were studied on various parameters related to energy metabolism in rat skeletal muscle mitochondria. The maximum activities related to complexes of the respiratory chain: rotenone-sensitive NADH-cytochrome c reductase, succinate-cytochrome c reductase, cytochrome c oxidase, state 3, state 4, uncoupled state, and respiratory control ratio were measured after 17-19 days of treatment. The results indicate that L-dopa treatment does not interfere with any of the parameters investigated and suggest that changes in muscle mitochondrial function found in parkinsonian patients are the result of the disease process and not its treatment.

引用

页码：315 / 319

页数：5

共 26 条

[1]

Mizuno Y, Ohta S, Tanaka M, Et al., Deficiencies in the complex I subunits of respiratory chain in Parkinson's disease, Biochem Biophys Res Commun, 163, pp. 1450-1455, (1989)

[2]

Schapira AHV, Mann VM, Cooper JM, Et al., Anatomic and disease specificity of NADH CoQ<sub>1</sub> reductase (complex I) deficiency in Parkinson's disease, J Neurochem, 55, pp. 2142-2145, (1990)

[3]

Parker WD, Boyson JB, Parks JK., Abnormalities of electron transport chain in idiopathic Parkinson's disease, Ann Neurol, 26, pp. 719-723, (1989)

[4]

Bindoff LA, Birch- M, Cartlidge NEF, Parker WD, Turnbull DM., Mitochondrial function in Parkinson's disease, Lancet, 2, (1989)

[5]

Segura-Aguilar J, Lind C., On the mechanism of the Mn<sup>3+</sup>‐induced neurotoxicity of dopamine: prevention of quinonederived oxygen toxicity by diaphorase and superoxide dismutase, Chemico-Biological Interactions, 72, pp. 309-324, (1989)

[6]

Graham DG., Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease, Neurotoxicology, 5, pp. 83-96, (1984)

[7]

Fariello RG, Calabrese V., Oxidative stress and energy transduction defects as causes of selective neuronal degeneration, Neurodegenerative disorders: the role played by endotoxins and xenobiotics, pp. 81-92, (1988)

[8]

Bellomo G, Jewell SA, Orrenius S., The metabolism of menadione impairs the ability of rat liver mitochondria to take up and retain calcium, J Biol Chem, 257, pp. 11558-11562, (1982)

[9]

Hillered L, Ernster L., Respiratory activity of isolated rat brain mitochondria following in vitro exposure to oxygen radicals, J Cereb Blood Flow Metab, 3, pp. 207-214, (1983)

[10]

Makinen MW, Lee CP., Biochemical studies of skeletal muscle mitochondria: I. Microanalysis of cytochrome content, oxidative and phosphorylative activities of mammalian skeletal muscle mitochondria, Arch Biochem Biophys, 126, pp. 75-82, (1968)

← 1 2 3 →